Answers are grounded in this paper and cite their sources.
Introduction The generation of human induced pluripotent stem cells (hiPSCs) with homogeneous and stable quality at an affordable cost is key to industrialize hiPSC-based cell therapies and drug development; however, conventional manual production is labor-intensive and difficult to standardize. Automated closed-system approaches can improve reproducibility, reduce contamination risk, and enable scale-out manufacturing, yet concerns remain regarding the quality of hiPSCs produced using this approach specialized in hiPSC generation from peripheral blood cells. Methods Here we developed a prototype semi-automated hiPSC production system to generate polyclonal hiPSC lines from peripheral blood cells. The semi-automated device consists of a spiral microfluidic module for leukocyte separation, followed by modules for leukocyte expansion culture and the transduction of a Sendai virus (SeV) vector carrying reprogramming factors. Subsequently, the transduced leukocytes were manually cultured and expanded to generate polyclonal hiPSC lines. Results The generated polyclonal hiPSC populations maintained a normal karyotype and carried minimal residual SeV vector. Importantly, they exhibited self-renewing capacity and pluripotency comparable to those of established clonal hiPSC lines. Furthermore, when subjected to directed differentiation towards cartilage and kidney organoids, the polyclonal hiPSC lines efficiently differentiated into these lineages. Conclusions The semi-automated system enabled the generation of high-quality polyclonal hiPSC lines, which will hold promise for future applications in cell therapy and drug development.
No takes yet. Share an insight, caveat, or question.
Hayashi et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: